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ABSTRACT:
Heat shock protein 90 (Hsp90) is a molecular chaperone required for the stability 
and function of multiple over-expressed signaling proteins that promote growth 
and survival in cancer cells. Chronic lymphocytic leukaemia (CLL) is characterized 
by increased expression of several Hsp90 client proteins making it a potentially 
susceptible to Hsp90 inhibition. In this study we showed that the novel Hsp90 inhibitor 
NVP-AUY922-AG was cytotoxic to primary CLL cells in vitro (LD50=0.18µM±0.20). 
Importantly, its toxicity was preserved under cytoprotective co-culture conditions that 
rendered fludarabine ineffective. At the molecular level, NVP-AUY922-AG depleted 
the expression of multiple Hsp90 client proteins including Akt and activators of NF-
κB, IKKα and IKKβ. Consistent with this inhibition profile, NVP-AUY922-AG resulted 
in decreased transcription of the NF-B target genes MCL1, CFLAR, BIRC5. In contrast, 
fludarabine significantly induced the transcription of MCL1 and BIRC5. Given the 
anti-apoptotic nature of these genes and the role they play in fludarabine resistance, 
we considered that the combination of NVP-AUY922-AG with fludarabine might 
resensitize CLL cells to the effects of fludarabine. In keeping with this hypothesis, 
the combination of NVP-AUY922-AG and fludarabine was highly synergistic (mean 
CI=0.110.06) and this synergy was enhanced in co-culture (mean CI=0.06±0.08). 
Furthermore, the combination maintained the decrease in MCL1, CFLAR and BIRC5 
transcription suggesting that the ability of NVP-AUY922-AG to modulate expression of 
these genes may contribute to the efficacy of this drug under cytoprotective co-culture 
conditions and for its remarkable synergy with fludarabine. Taken together these 
findings indicate that Hsp90 inhibition is an attractive therapeutic strategy in CLL. 
INTRODUCTION
B cell chronic lymphocytic leukemia (CLL) is the 
most common leukemia in the western world and is 
characterized by an accumulation of monoclonal mature 
B cells within lymphoid organs, bone marrow and 
peripheral blood [1]. Microenvironments within the bone 
marrow and lymph nodes play a prominent role in CLL 
[1] as proliferation of CLL cells occurs in these centers 
[2]. It is now clear that CLL cell survival and activation 
is promoted by bone marrow stromal cells, follicular 
dendritic cells and T cells in vivo [1]. Furthermore, co-
culture with bone marrow stromal cells in vitro can 
inhibit CLL cell apoptotic responses to purine analog 
chemotherapy through anti-apoptotic signals derived from 
CLL cell-stromal cell contact [3]. This microenvironment-
derived cytoprotection against chemotherapeutic drugs 
likely contributes to treatment failure and relapse in CLL. 
Recently published gene expression profiling supports 
this view as lymph node-derived CLL cells showed a 
profile  consistent  with  enhanced  tumor  proliferation 
and activation of the NF-κB pathway [2]. Other genes, 
including the inhibitor of apoptosis Survivin, are induced 
by  NF-κB  signaling  via  CD40-CD40L  interaction  [1] 
and in vivo Survivin-expressing cells are confined to the 
lymph node and pseudo follicles in the bone marrow [1].
Heat shock protein 90 (Hsp90) is part of the cellular Oncotarget 2012; 3:  525-534 526 www.impactjournals.com/oncotarget
Figure 1: NVP-AUY922-AG is more cytotoxic that fludarabine, retains its activity in cytotoxic culture conditions and 
induces apoptosis in CLL cells in vitro. A) Culture of CLL cells in vitro in the presence of IL-4 reduces the level of spontaneous 
apoptosis seen after 48h (P < 0.0001). NTL or CD40L expressing co-culture resulted in cytoprotection of CLL cells in culture (NTL P < 
0.0001, CD40L P = 0.0003). B) LD50 values for CLL cells treated with NVP-AUY922-AG and fludarabine in vitro for 48h showed that 
cytotoxic effect of fludarabine was significantly reduced by the presence of IL-4 in culture (P = 0.048) while NVP-AUY922-AG was not. C) 
NVP-AUY922-AG retains cytotoxic activity on CLL cells in vitro in 48h treatments in suspension culture and in cyto-protective co-culture 
conditions. No differences in mean LD50 in CLL cells were significant. D) Dose response of CLL cells to NVP-AUY922-AG. Apoptosis 
was confirmed by annexin V and PI staining and visualization by flow cytometry and compared to an untreated population shown in E. 
Untreated                         0.01μM                     0.04μM 
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chaperoning machinery that plays a role in maintaining 
protein functions including trafficking, post-translational 
stability and turnover of its protein substrates (clients) 
[4, 5]. Inhibition of Hsp90 function leads to proteasomal 
degradation of Hsp90 client proteins [4] and in theory 
results in simultaneous blockade of multiple oncogenic 
signaling cascades [5]. Cancer cells often contain elevated 
levels of Hsp90 [5] but the data on CLL cells is equivocal 
since there are conflicting reports on the relative level of 
Hsp90 expression in CLL cells and normal peripheral 
blood mononuclear cells [6, 7]. However, Hsp90 inhibitors 
have previously been shown to have activity in CLL 
cells [6] and the resulting toxicity was shown to partly 
attributable  to  the  inhibition  of  NF-κB  [8].  NF-κB  is 
commonly up-regulated in CLL [9] and is maintained, at 
least in part, by interactions with the microenvironment 
[10].  Furthermore,  NF-κB  has  been  shown  to  be  a 
therapeutic target in CLL [9, 11] but no specific NF-κB 
inhibitors are currently available for the treatment of this 
disease.
In this study we assessed the effect of the Hsp90 
inhibitor NVP-AUY922-AG, as a single agent and in 
combination with fludarabine, on CLL cells under different 
cell culture conditions. We examined the effects of Hsp90 
inhibition  on  Hsp90  client  proteins  and  downstream 
signaling pathways and evaluated the potential for synergy 
with fludarabine. 
RESULTS 
IL-4 and co-culture with NTL and CD40L cells 
reduce spontaneous apoptosis in vitro CLL cell 
culture
Previous studies have shown that the addition of 
IL-4 to CLL culture enhances in vitro survival by inducing 
resistance to apoptosis [12, 13]. In this study we confirmed 
that the addition of IL-4 to CLL cell cultures resulted in 
a significant reduction in spontaneous apoptosis after 48h 
(31.4% to 14.1%, P<0.0001). Co-culture with either NTL 
Figure 2: Known Hsp90 client proteins AKT, IKKα and IKKβ are depleted by NVP-AUY922-AG. Two representative 
samples are shown of CLL cells treated with NVP-AUY922-AG in vitro. Western blotting showed depletion of AKT, IKKα and IKKβ 
proteins in a concentration dependent manner (µM) after treatment with NVP-AUY922-AG for 24h. Images were quantified by densitometry 
and the level of expression relative to untreated control and tubulin expression if shown under each band of protein. Expression of the 
MAPK protein was not appreciably decreased by NVP-AUY922-AG while expression of both Hsp90 and Hsp70 proteins was increased.
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or CD40L cells proved even more cytoprotective for CLL 
cells (Figure 1A; P = 0.005 and P = 0.034 respectively); 
addition  of  IL-4  to  these  co-cultures  did  not  further 
enhance  the  cytoprotection  (NTL:  P  =  0.31,  CD40L: 
P = 0.07). As a result of these findings, all subsequent 
experiments were carried out in suspension cultures 
supplemented with IL-4 and in co-culture with NTL and 
CD40L cells unless stated otherwise.
NVP-AUY922-AG  is  more  potent  than 
fludarabine and retains toxicity in the presence 
of IL-4 and in NTL and CD40L expressing co-
culture
The  Hsp90  inhibitor,  NVP-AUY922-AG  was 
almost a log more potent than fludarabine in CLL cells 
cultured in suspension without IL-4. The mean LD50 for 
the Hsp90 inhibitor NVP-AUY922-AG was 0.18µM ± 
0.20 and was 1.16 ± 1.74 for fludarabine. Furthermore, 
NVP-AUY922-AG retained its potency against primary 
CLL cells even in the presence of IL-4 (Figure 1B, P = 
0.43, Table 1.) whereas the cytotoxic effects of fludarabine 
were significantly attenuated under these conditions (P = 
0.008, Table 1). Furthermore, co-culturing CLL cells with 
NTL or CD40L cells completely abrogated the ability 
of fludarabine to induce cell death. In contrast, NVP-
AUY922-AG retained the ability to kill cells under these 
cytoprotective conditions (Figure 1C, Table 1, NTL P = 
0.85, CD40L P = 0.11). Figure 1D shows a composite 
dose-response curve for 3 individual CLL patients. We 
went  on  to  confirm  that  NVP-AUY922-AG-induced 
cytotoxicity was mediated via apoptosis and this was 
apparent even at concentrations as low as 0.01µM (Figure 
1E).
NVP-AUY922-AG depletes AKT, IKKα and IKKβ 
proteins
We  went  on  to  investigate  the  effects  of  NVP-
AUY922-AG on number of known pro-survival Hsp90 
client proteins AKT, IKKα and IKKβ [8, 14, 15]. All 
three proteins were depleted in CLL cells treated with 
NVP-AUY922-AG for 24h in a concentration-dependent 
manner (Figure 2). In contrast, MAPK, another Hsp90 
client protein, was not substantially decreased at low NVP-
AUY922-AG concentrations (0.01-0.04µM) suggesting a 
degree of selectivity for NVP-AUY922-AG (Figure 2). In 
keeping with previous studies, [16, 17] the inhibition of 
Hsp90 resulted in an increase in Hsp70 protein expression 
(Figure 2). It is worthy of note that Hsp90 itself was 
not diminished in our assay system but NVP-AUY922-
AG inhibits ATPase activity at the N-terminus of Hsp90 
thereby promoting client protein dissociation rather than 
Hsp90 protein degradation [18].
NVP-AUY922-AG  is  highly  synergistic  with 
fludarabine
Given  that  fludarabine-based  regimens  are  the 
standard of care for the treatment of CLL [19-21], we 
assessed the effects of combining fludarabine with NVP-
AUY922-AG in vitro. The combination of these drugs 
resulted in remarkably strong synergy in the absence 
of IL-4 and this was further enhanced by the addition 
of IL-4 to the cultures (Figure 3A, mean CI at LD50; 
-IL-4  =  0.11±0.06,  +IL-4  =  0.06±0.08).  Furthermore, 
the  synergistic  interaction  between  NVP-AUY922-
AG  and  fludarabine  was  observed  over  a  wide  range 
of concentrations in all the culture conditions tested 
(Figure 3B). Given that we have shown that fludarabine 
resistance is markedly increased in the presence of IL-4, 
it seems likely that the increased synergy seen under these 
conditions is promoted, at least in part, by the ability of 
NVP-AUY922-AG to reverse IL-4-mediated fludarabine 
resistance mechanisms.
In an attempt to investigate the mechanistic basis 
of the synergy observed between NVP-AUY922-AG and 
fludarabine, we examined the effect of both agents, alone 
and in combination, on the expression of AKT, MAPK, 
IKKα  and  IKKβ  proteins  in  CLL  cells.  Both  NVP-
AUY922-AG  and  fludarabine  reduced  the  expression 
of all four proteins at concentrations employed in the 
synergy experiments (Figure 3C). The decrease in these 
Table 1
IL-4 n
NVP-AUY922-AG
LD50 µM ± SD
n
Fludarabine
LD50 µM ± SD
Suspension - 9 0.18  ± 0.20 13 1.16 ± 1.74
+ 26 1.25 ± 3.54 25 13.12 ± 20.89
NTL - 3 0.14 ± 0.06 4 >100 ± -
+ 22 1.41 ± 1.60 32 >100 ± -
CD40L - 3 0.27 ± 0.15 4 >100 ± -
+ 24 5.791 ± 13.75 32 >100 ± -Oncotarget 2012; 3:  525-534 529 www.impactjournals.com/oncotarget
proteins was enhanced when the agents were used in 
combination. In contrast, Hsp90 protein expression was 
not altered by the combination of NVP-AUY922-AG and 
fludarabine. Hsp70 protein expression was increased by 
NVP-AUY922-AG  and  NVP-AUY922-AG  combined 
with fludarabine but was slightly decreased by fludarabine 
alone.
NVP-AUY922-AG  inhibits  NF-κB  target  gene 
transcription
Given the inhibitory effects of NVP-AUY922-AG 
on IKKα and IKKβ, we next investigated genes that are 
transcriptionally regulated by NF-κB. In particular we 
investigated transcriptional changes in the anti-apoptotic 
genes BCL2, MCL1, CFLAR and BIRC5 as well as 
the pro-inflammatory cytokine IL-1β. We measured the 
relative level of target gene mRNA expression, when 
compared with the house-keeping gene RPS14, following 
treatment  of  primary  CLL  cells  with  NVP-AUY922-
AG, fludarabine and the combination for 4 hours and 24 
hours. Transcription of the short half-life genes MCL1, 
CFLAR  and  BIRC5  were  significantly  inhibited  at  4 
hours  following  treatment  with  2µM  NVP-AUY922-
AG  and  the  combination  of  NVP-AUY922-AG  and 
fludarabine  (Figure  4A).  In  contrast,  treatment  with 
4µM fludarabine as a single agent did not significantly 
reduce  the  transcription  of  these  genes  at  the  4-hour 
time point. A similar pattern of expression was observed 
following exposure to drug for 24 hours; all of the NF-
κB regulated genes were significantly inhibited following 
exposure  to  NVP-AUY922-AG  and  the  combination 
Figure  3:  NVP-AUY922-AG  is  strongly  synergistic 
with fludarabine and Akt, IKKα and IKKβ are strongly 
depleted  by  NVP-AUY922-AG  and  fludarabine  in 
combination.  A)  NVP-AUY922-AG  and  fludarabine  were 
combined at a constant ratio (1:2) in vitro and the CI calculated 
at  the  ED50 concentration  calculated  were  CI  <  1  indicates 
synergy between NVP-AUY922-AG and fludarabine. Strongly 
synergy between the two drugs was indicated in suspension 
culture  and  in  the  cytoprotective  CD40L  expressing  culture 
conditions. Samples refractory to fludarabine in vitro showed 
synergy between the two drugs in all culture conditions. B) 
Synergy was shown over a range of concentrations of the drugs 
used. In the majority of cases, the level of synergy appeared to 
be stronger towards higher ED values. C) NVP-AUY922-AG 
and fludarabine result in the depletion of expression of AKT, 
MAPK, IKKα and IKKβ proteins. The effect of fludarabine as a 
single agent on expression of all four proteins is smaller than that 
induced by NVP-AUY922-AG. Combination of Fludarabine and 
NVP-AUY922-AG produced a larger decrease in expression of 
these proteins enforcing the mechanism of synergy between the 
drugs at a molecular level. Quantitation of the level of protein 
expression is shown below the relevant blot and is relative to 
α-tubulin expression.
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of  NVP-AUY922-AG  and  fludarabine  (Figure  4B). 
Importantly, exposure to fludarabine alone appeared to 
induce the transcription of MCL1 and BIRC5 at 24 hours 
consistent with the view that these genes may play a 
role in facilitating fludarabine resistance in vitro [1, 22]. 
Furthermore, the combination of NVP-AUY922-AG and 
fludarabine suppressed the fludarabine-mediated induction 
of MCL1 and BIRC5. It is therefore conceivable that that 
NVP-AUY922-AG-mediated inhibition of anti-apoptotic 
genes would increase the sensitivity of primary CLL cells 
to the effects of fludarabine in the combination thereby 
contributing to the synergy seen with these agents.
DISCUSSION
CLL is an incurable disease using the standard 
therapeutic options currently available [23, 24]. Although 
most patients initially respond to chemotherapy, they 
invariably relapse and develop drug resistance. There is 
growing evidence that resistance arises in the pro-survival 
microenvironments found in the lymph nodes and bone 
marrow [25] and both cellular and humoral interactions 
in these tissue sites likely play a role in this process [26]. 
Recent evidence suggests that the lymph node interactions 
preferentially induce CLL cell activation and proliferation 
when compared to the bone marrow microenvironment 
[2] and this is associated with the activation of the NF-κB 
pathway. NF-κB target genes are involved in cell-cycle 
regulation, inhibition of apoptosis, signal transduction 
and chemotaxis [2]. In the lymph node microenvironment 
CD40-CD40L  interactions  between  CLL  cells  and 
activated  T-cells  induces  NF-κB,  drives  CLL  cell 
proliferation and promotes resistance to chemotherapeutics 
[27].  Consequently,  recent  research  has  focused  on 
targeting the microenvironment and the signaling 
pathways within CLL cells that it activates [25]. However, 
cancer cells are adept at circumventing pharmacological 
blockade of individual signaling pathways so the concept 
of multiple targeted approaches appears rational (24). In 
this context, inhibition of Hsp90 is an attractive possibility 
in CLL and other cancers [28-31] as Hsp90 is a molecular 
chaperone that acts to ensure the correct folding of 
nascent proteins and their maintenance or targeting for 
degradation by the proteasome. Inhibition of Hsp90 has 
been reported to simultaneously down regulate a number 
of client proteins that are involved in signaling pathways 
implicated in cancer [28, 31].
Given  the  importance  of  microenvironmental 
effects on CLL cells, it is increasingly clear that potential 
treatments for CLL should be evaluated under conditions 
Figure 4: NF-κB regulated genes are inhibited by NVP-AUY922-AG. Anti-apoptotic genes BCL2, MCL1, CFLAR, BIRC5 and 
inflammatory cytokine IL-1β are all regulated by NF-κB. Real-time reverse-transcription PCR was used to measure the relative level of 
target gene mRNA expression compared to housekeeping gene RPS14 following treatment with NVP-AUY922-AG, fludarabine and both 
in combination. A) 4h of treatment with NVP-AUY922-AG (2µM) and NVP-AUY922-AG with fludarabine significantly inhibited MCL1, 
CFLAR and BIRC5. Fludarabine alone did not reduce the mRNA level of these genes. B) MCL1, CFLAR, BIRC5 and IL-1β mRNA levels 
were all reduced by 24h treatment with NVP-AUY922-AG or NVP-AUY922-AG and fludarabine in combination. Fludarabine as a single 
agent induced mRNA expression of MCL1 and BIRC5. * P < 0.05, ** P < 0.0001.Oncotarget 2012; 3:  525-534 531 www.impactjournals.com/oncotarget
that mimic these pro-survival niches. Therefore, in this 
study  we  added  IL-4  to  liquid  culture  conditions  and 
used mouse fibroblast co-cultures which promote the up-
regulation of co-stimulatory and adhesion molecules in 
the CLL cells [32]. Both of these approaches significantly 
reduced the level of spontaneous apoptosis seen after 48h 
[33, 34]. The addition of IL-4 to liquid culture conditions 
induced marked resistance to fludarabine. Resistance to 
apoptosis  induced  by  fludarabine  has  previously  been 
described in CLL cells cultured with CD40L-expressing 
cells in the presence of IL-4.[35] The mechanism(s) for 
this have not been fully elucidated but the upregulation of 
Bcl-2 may well be a contributory factor.[33] In contrast, 
NVP-AUY922-AG was equipotent in IL-4 supplemented 
cultures suggesting that its mechanism of killing was 
distinct from fludarabine. Furthermore, under co-culture 
conditions on NTL of CD40L cells fludarabine was even 
less cytotoxic whereas NVP-AUY922-AG retained its 
cell  killing  activity. The  cell  killing  activity  of  NVP-
AUY922-AG  in  the  co-culture  systems  is  promising 
as it suggests that this agent can overcome the survival 
signals induced in the CLL cells by interactions with the 
microenvironment including CD40-CD40L signaling and 
protection by IL-4 [36].
At  the  molecular  level,  we  demonstrated  Hsp90 
inhibition  resulted  in  an  increase  in  Hsp70;  a  finding 
consistent with previously published reports of Hsp90 
inhibitors.[16, 17] It is worthy of note that the induction of 
Hsp70 expression as a result of Hsp90 inhibition may be 
problematic as Hsp70 is a cytoprotective protein that can 
block both caspase-dependent and caspase-independent 
apoptosis, and also autophagic cell death and necrosis 
[28].  However,  the  stability  and  function  of  multiple 
client proteins are regulated by Hsp90 and these proteins 
function as regulators of cell growth, differentiation and 
in  apoptotic  pathways[37].  Consequently,  inhibition 
of  Hsp90  function  by  NVP-AUY922-AG  resulted  in 
decreased expression of AKT, MAPK, IKKα and IKKβ. 
This confirms that inhibition of Hsp90 targets multiple 
signaling pathways. [14, 15] Of particular interest is the 
inhibition of IKK and IKKβ as these modulate expression 
of NF-κB through phosphorylation of IκB leading to IκB 
degradation  and  subsequent  release  and  activation  of 
NF-κB.[38, 39] NF-κB has been previously shown to be 
a prognostic marker and a therapeutic target in CLL [9, 
11, 40] and the ability to suppress NF-κB activation in 
CLL cells may be critical to the success of a treatment. 
We have recently shown that NF-κB activation is higher in 
previously treated CLL patients [40], which in turn makes 
the cells impervious the effects of other therapies [41].
The  most  striking  finding  of  this  study  was  the 
remarkable cytotoxic synergy seen in CLL cells treated 
with NVP-AUY922-AG and fludarabine, particularly in 
cytoprotective culture conditions (Figure 3). This synergy 
was mirrored at the molecular level as the inhibition of 
AKT,  IKKα  and  IKKβ  by  NVP-AUY922-AG  alone 
was  enhanced  when  NVP-AUY922-AG  was  used  in 
combination with fludarabine. Additionally, co-culture of 
CLL cells with CD40L-expressing cells results in the up-
regulation of anti-apoptotic genes including NF-κB target 
genes BCL2 and MCL1 [42, 43], CFLAR and BIRC5 [44]. 
Quantitative PCR analysis showed that NVP-AUY922-
AG resulted in inhibition of expression of MCL1, CFLAR 
and BIRC5 in primary CLL cells (Figure 4). In contrast, 
fludarabine  induced  the  transcription  of  MCL1  and 
BIRC5. Importantly, the combination of NVP-AUY922-
AG and fludarabine resulted in the net transcriptional 
repression of these genes perhaps providing a molecular 
explanation for the synergy observed. 
In  conclusion,  inhibition  of  Hsp90  appears  to 
be an attractive prospective for therapy in CLL as 
it targets multiple intracellular signaling pathways 
that are preferentially activated in cytoprotective 
microenvironments  in  vivo.  Encouragingly,  NVP-
AUY922-AG retained its activity in the presence of such 
signals in vitro and showed remarkable synergy with 
fludarabine under the same conditions. As such, early 
phase trials of this agent, both alone and in combination, 
would seem warranted.
MATERIALS AND METHODS
Cell isolation and culture
Lymphocytes from peripheral blood samples from 
CLL  patients  were  separated  using  Ficoll-Hypaque 
(Sigma, Poole, UK). Samples were washed in phosphate 
buffered  saline  (PBS)  and  counted.  Patients  were 
diagnosed using a combination of clinical criteria and 
immunophenotyping. Informed consent was obtained in 
accordance with the ethical approval obtained from South 
East Wales Research Ethics Committee (02/4806) prior 
to samples being taken. Separated lymphocytes were 
maintained in RPMI medium supplemented with 10% fetal 
bovine serum (FBS), penicillin (50U/ml) and streptomycin 
(50µg/ml). Where indicated, recombinant human IL-4 (R 
and D Systems, Abingdon, UK) (5ng/ml) was added to 
the culture medium (5ng/ml). Mouse embryonic fibroblast 
L-cells, either non-transfected (NTL) or L-cells expressing 
CD40 ligand (CD40L) [45] were used where indicated as 
feeder layers. 
Toxicity assays 
The toxicity of the Hsp90 inhibitor NVP-AUY922-
AG  in  primary  CLL  cells  was  determined  in  cells  in 
suspension culture, on NTL and CD40L feeder layers 
over 48h both in the presence and absence of IL-4. NVP-
AUY922-AG  was  tested  at  concentrations  between 
0.008µM and 50µM. Sensitivity to fludarabine (0.15µM Oncotarget 2012; 3:  525-534 532 www.impactjournals.com/oncotarget
to 10µM) was also measured in the same samples. CLL 
cells co-cultured on a feeder layer were pretreated with 
NVP-AUY922-AG or fludarabine for 2 hours before being 
placed on the feeder layer to preserve the integrity of the 
layer and ensure that only the CLL cells were exposed to 
drug. Cell viability was assessed by flow cytometry.
Synergy 
Synergy between NVP-AUY922-AG and fludarabine 
was tested in suspension culture (± IL-4) and on CD40L 
cells  (with  IL-4)  over  48h. A  constant  molar  ratio  of 
NVP-AUY922-AG 1:2 fludarabine was used based on 
the relative activities of both agents determined in the 
preceding toxicity experiments. Concentrations used were 
NVP-AUY922-AG  (0.001  to  50µM)  and  fludarabine 
(0.002 to 100µM). Cell death was assessed on an Accuri 
C6 flow cytometer (BD Accuri Cytometers, Ann Arbor, 
MI,  USA).  Synergy  was  calculated  according  to  the 
median effect method using CalcuSyn software [46].
Annexin V positivity
CLL lymphocytes treated with NVP-AUY922-AG 
(0.01, 0.02, 0.04, 2.0 and 4.0µM) for 48h were tested 
for annexin V positivity using an Annexin V apoptosis 
detection kit (Axxora Ltd, Matford Court, UK) according 
to the manufacturer’s instructions. Untreated cells were 
used a control. Cells treated with NVP-AUY922-AG were 
maintained in suspension culture with IL-4. 
Immunoblotting 
Equal  numbers  of  cells  (5  x  106 cells) treated 
with NVP-AUY922-AG (0, 0.01, 0.02 and 0.04µM) in 
suspension culture with IL-4 for 24h were washed with 
PBS and lyzed by resuspension in lysis buffer (HEPES 
50mM,  sodium  fluoride  5mM,  iodoacetamide  5mM, 
sodium chloride 75mM, NP40 1%, PMSF 1mM, sodium 
orthovanadate  1mM,  protease  inhibitors  (Sigma)  1%, 
phospatase inhibitor cocktail 2 (Sigma) 1%, phosphatase 
inhibitor cocktail 3 (Sigma) 1%) for 30 minutes at 4oC 
followed by centrifugation at 16 000 x g. Clarified lyzates 
were subjected to electrophoresis using NuPage precast 
4-12% Bis-Tris gels (Invitrogen, Paisley, UK) followed 
by transfer to PVDF membranes (GE Healthcare UK Ltd, 
Little Chalfont, UK). Immunoblotting was performed with 
antibodies to Hsp90, Akt, mitogen-activated protein kinase 
(MAPK), IκB kinase α (IKKα), IκB kinase β (IKKβ) 
(New England Biolabs (UK) Ltd, Hitchin, UK), Hsp70 
(Millipore (UK) Ltd, Watford, UK), Tubulin (Abcam, 
Cambridge, UK). Cells treated with NVP-AUY922-AG 
and fludarabine in combination (NVP-AUY922-AG 0.02 
and 0.04µM, fludarabine 2.0 and 4.0 µM) in suspension 
culture with IL-4 for 24h at the ratio previously described 
were also lyzed and immunoblotted with the same panel of 
antibodies. Additionally, cells treated with NVP-AUY922-
AG on CD40L cells with IL-4 for 24h were also lyzed and 
immunoblotted for the same panel of antibodies.
Real-time reverse transcription-PCR
Untreated cells and cells treated with NVP-AUY922-
AG and fludarabine in combination (NVP-AUY922-AG 
2.0µM, fludarabine 4.0µM and both drugs at a ratio of 
1:2) for 4 and 24h. 5x106 CLL cells were re-suspended 
in 1ml Trizol reagent and RNA was extracted using 
chloroform and isopropanol. RNA (1 μg) was used in a 
20μL reverse transcription (RT) reaction containing 10× 
Buffer II, 5 mmol/L MgCl2, 0.5 μmol/L deoxynucleotide 
triphosphates, 2.5 units reverse transcriptase, 1 unit RNase 
inhibitor, and 2.5 μmol/L random hexamers. cDNA (2 
μL) was placed into the RT-PCR reaction. SYBR Green 
technology (Roche Diagnostics, Burgess Hill, UK) was 
used  to  quantify  the  amount  of  RNA  present  in  each 
sample using primer pairs for BCL2, MCL1, CFLAR, 
BIRC5, IL-1β and RPS14. All primers were purchased 
from Eurogentec Ltd (Southampton, UK). The amount of 
mRNA was assessed using real-time RT-PCR using the 
LightCycler System (Roche Diagnostics). The amount of 
RPS14 mRNA was quantified in all samples as an internal 
house-keeping control, and the results of the real-time RT-
PCR were expressed as normalized target gene values (e.g. 
the ratio between BCL2 and RPS14 transcripts calculated 
from the crossing points of each gene). All experiments 
were performed in duplicate. Total RNA was amplified 
using the following primers: 
BCL2:  5′-aagattgatgggatcgttgc-3′  (forward)  and 
5′-tgtgctttgcattcttggac-3′ (reverse); 
MCL1: 5′-aaaagcaagtggcaagagga-3′ (forward) and 
5′-ttaatgaattcggcgggtaa-3′ (reverse); 
CFLAR: 5′-gtggagacccacctgctca-3′ (forward) 
and 5′-ggacacatcagatttatccaaatcc-3′ (reverse); 
BIRC5: 5′-ttagcagaaaatgcactccag-3′ (forward) and 
5′-ctggttttaaggatggccttt-3′ (reverse); 
IL-1β:  5′-tggcagaaagggaacagaaa-3′  (forward)  and 
5′-acttcttgccccctttgaat-3′ (reverse); 
RPS14: 5′-ggcagaccgagatgaactct-3′ (forward) and 
5′-ccaggtccaggggtcttggt-3′ (reverse). 
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